These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29855987)

  • 21. [Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan].
    Tsuji Y; Nakayama T; Bono K; Kitamura M; Imafuku I
    Rinsho Shinkeigaku; 2014; 54(5):423-8. PubMed ID: 24943080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM; Gamret AC; Darwin E; Gaudi S
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delaying treatment in male-pattern hair loss affects the therapeutic response.
    Rushton DH; Gilkes JJ
    Clin Exp Dermatol; 2011 Mar; 36(2):204-5. PubMed ID: 20659117
    [No Abstract]   [Full Text] [Related]  

  • 24. The efficacy and use of finasteride in women: a systematic review.
    Hu AC; Chapman LW; Mesinkovska NA
    Int J Dermatol; 2019 Jul; 58(7):759-776. PubMed ID: 30604525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 'Post-finasteride syndrome': what to tell our female patients?
    Mervis JS; Borda LJ; Miteva M
    Br J Dermatol; 2018 Sep; 179(3):785-786. PubMed ID: 29624646
    [No Abstract]   [Full Text] [Related]  

  • 26. Finasteride-associated male infertility.
    Chiba K; Yamaguchi K; Li F; Ando M; Fujisawa M
    Fertil Steril; 2011 Apr; 95(5):1786.e9-11. PubMed ID: 21193189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finasteride Topical Delivery Systems for Androgenetic Alopecia.
    Khan MZU; Khan SA; Ubaid M; Shah A; Kousar R; Murtaza G
    Curr Drug Deliv; 2018; 15(8):1100-1111. PubMed ID: 29366416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of finasteride polymer microspheres for systemic application in androgenic alopecia.
    Kim JH; Na J; Bak DH; Lee BC; Lee E; Choi MJ; Ryu CH; Lee S; Mun SK; Park BC; Kim BJ; Lee HS
    Int J Mol Med; 2019 Jun; 43(6):2409-2419. PubMed ID: 30942390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss.
    Guo M; Heran B; Flannigan R; Kezouh A; Etminan M
    Pharmacotherapy; 2016 Nov; 36(11):1180-1184. PubMed ID: 27644029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia?
    Motofei IG; Rowland DL; Georgescu SR; Tampa M; Baleanu BC; Paunica S
    Exp Dermatol; 2016 Jul; 25(7):557-8. PubMed ID: 26990657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
    Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
    Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
    Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
    JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.
    Caserini M; Radicioni M; Leuratti C; Terragni E; Iorizzo M; Palmieri R
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):19-27. PubMed ID: 26636418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elective cesarean section or not? Maternal age and risk of adverse outcomes at term: a population-based registry study of low-risk primiparous women.
    Herstad L; Klungsøyr K; Skjærven R; Tanbo T; Forsén L; Åbyholm T; Vangen S
    BMC Pregnancy Childbirth; 2016 Aug; 16():230. PubMed ID: 27535233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia.
    Ryu HJ; Kwon DY
    Dermatol Surg; 2014 May; 40(5):595-7. PubMed ID: 24533595
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cesarean section on request at 39 weeks: impact on shoulder dystocia, fetal trauma, neonatal encephalopathy, and intrauterine fetal demise.
    Hankins GD; Clark SM; Munn MB
    Semin Perinatol; 2006 Oct; 30(5):276-87. PubMed ID: 17011400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Postoperative Finasteride Therapy on Recurrence of Gynecomastia After Mastectomy in Men Taking Finasteride for Alopecia.
    Lee SG; Park PJ; Lee SR; Koo BH; Byun GY; Kim MJ; Kang HJ; Kim S; Oh BS; Lee YH
    Am J Mens Health; 2019; 13(5):1557988319871423. PubMed ID: 31552775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.